Plasma disposition and tissue depletion of difloxacin and its metabolite sarafloxacin in the food producing animals, chickens for fattening

Abd El-Aty, 2005, Disposition kinetics of difloxacin in rabbit after intravenous and intramuscular injection of Dicural, Vet. Res. Commun., 29, 297, 10.1023/B:VERC.0000048503.05426.68 Abo-El-Sooud, 2008, Pharmacokinetics and intramuscular bioavailability of difloxacin in dromedary camels (Camelus dromedarius), Vet. J., 179, 282, 10.1016/j.tvjl.2008.05.011 Adams, 2005, Pharmacokinetics of difloxacin and its concentration in body fluids and endometrial tissues of mares after repeated intragastric administration, Can. J. Vet. Res., 69, 229 Anderson, 2003, Public health consequences of use of antimicrobial agents in food animals in the United States, Microb. Drug Resist., 9, 373, 10.1089/107662903322762815 Angulo, 2000, Origins and consequences of antimicrobial-resistant nontyphoidal Salmonella: implications for the use of fluoroquinolones in food animals, Microb. Drug Resist., 6, 77, 10.1089/mdr.2000.6.77 Boxenbaum, 1998, Pharmacokinetics tricks and traps: flip-flop models, J. Pharm. Pharm. Sci., 1, 90 EMEA (The European Agency for the Evaluation of Medicinal Products), 1998. Guideline on Validation of Analytical Procedures: Methodology (VICH GL2). CVMP/VICH/591/98-FINAL, pp. 1–10. EMEA (The European Agency for the Evaluation of Medicinal Products), 2002a. Committee for Veterinary Medicinal Products. Summary Report on Difloxacin (Extension to all food producing species). EMEA/MRL/819/02-FINAL, pp. 1–2. EMEA (The European Agency for the Evaluation of Medicinal Products), 2002b. Updated Application Software relating to Note for Guidance on Approach towards Harmonisation of Withdrawal Periods for Meat. EMEA/CVMP/563/02, p. 1. Bansal, 1987, Activity of difloxacin (A-56619) and A-56620 against clinical anaerobic bacteria in vitro, Antimicrob. Agents Chemother., 31, 619, 10.1128/AAC.31.4.619 Barry, 1986, In vitro evaluation of A-56619 and A-56620, two new quinolones, Antimicrob. Agents Chemother., 29, 40, 10.1128/AAC.29.1.40 Chu, 1989, Sctructure-activity relationships of the fluoroquinolones, Antimicrob. Agents Chemother., 33, 131, 10.1128/AAC.33.2.131 Chu, 1985, ABBOTT-56619, Drugs Future, 10, 543, 10.1358/dof.1985.010.07.66379 Cozzarelli, 1980, DNA gyrase and the supercoiling of DNA, Science, 207, 953, 10.1126/science.6243420 Craig, 1998, Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men, Clin. Infec. Dis., 26, 1, 10.1086/516284 Dalla Costa, 1996, AUIC – a general target for the optimisation of dosing regimens of antibiotics?, Ann. Pharmacother., 30, 1024, 10.1177/106002809603000919 Ding, 2008, Pharmacokinetics of difloxacin in pigs and broilers following intravenous, intramuscular, and oral single-dose applications, J. Vet. Pharmacol. Ther., 31, 200, 10.1111/j.1365-2885.2008.00951.x Drlica, 1984, Biology of bacterial deoxyribonucleic acid topoisomerases, Microbiol. Rev., 48, 273, 10.1128/MMBR.48.4.273-289.1984 Drlica, 1997, DNA gyrase, topoisomerase IV, and the 4-quinolones, Microbiol. Mol. Biol. Rev., 61, 377, 10.1128/.61.3.377-392.1997 Drusano, 1993, Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis, Antimicrob. Agents Chemother., 37, 483, 10.1128/AAC.37.3.483 Dudley, 1991, Pharmacodynamics and pharmacokinetics of antibiotics with special reference to the fluoroquinolones, Am. J. Med., 91, 45, 10.1016/0002-9343(91)90311-K Eliopoulos, 1985, In vitro activity of the quinolone antimicrobial agents A-56619 and A-56620, Antimicrob. Agents Chemother., 28, 514, 10.1128/AAC.28.4.514 Fernandes, 1986, In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones, Antimicrob. Agents Chemother., 29, 201, 10.1128/AAC.29.2.201 Fernández-Varón, 2006, Pharmacokinetics of difloxacin after intravenous, intramuscular, and intragastric administration to horses, Am. J. Vet. Res., 67, 1076, 10.2460/ajvr.67.6.1076 Forrest, 1993, Pharmacodynamics of IV ciprofloxacin in seriously ill patients, Antimicrob. Agents Chemother., 37, 1073, 10.1128/AAC.37.5.1073 Frazier, 2000, Comparison of fluoroquinolone pharmacokinetic parameters after treatment with marbofloxacin, enrofloxacin and difloxacin in dogs, J. Vet. Pharmacol. Ther., 23, 293, 10.1046/j.1365-2885.2000.00285.x Gellert, 1981, DNA topoisomerases, Annu. Rev. Biochem., 50, 879, 10.1146/annurev.bi.50.070181.004311 Gerchman, 2008, In vitro susceptibilities to fluoroquinolones in current and archived Mycoplasma gallisepticum and Mycoplasma synoviae isolates from meat-type turkeys, Vet. Microbiol., 131, 266, 10.1016/j.vetmic.2008.04.006 Granneman, 1986, Difloxacin metabolism and pharmacokinetics in humans after single oral doses, Antimicrob. Agents Chemother., 26, 689, 10.1128/AAC.30.5.689 Hardee, 1998, Development and formulations of veterinary dosage forms, 100, 10.1201/b14210 Heinen, 2002, Comparative serum pharmacokinetics of the fluoroquinolones enrofloxacin, difloxacin, marbofloxacin, and orbifloxacin in dogs after single oral administration, J. Vet. Pharmacol. Ther., 25, 1, 10.1046/j.1365-2885.2002.00381.x Hooper, 1993, Mechanism of quinolone action and bacterial killing, 53 Humphrey, 2005, Prevalence and subtypes of ciprofloxacin-resistant Campylobacter spp. in commercial poultry flocks before, during, and after treatment with fluoroquinolones, Antimicrob. Agents Chemother, 49, 690, 10.1128/AAC.49.2.690-698.2005 Hyatt, 1995, The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents, Clin. Pharmacokinet., 28, 143, 10.2165/00003088-199528020-00005 Inui, 1998, Pharmacokinetic properties and oral bioavailabilities of difloxacin in pig and chicken, Xenobiotica, 28, 887, 10.1080/004982598239128 Ismail, 2007, Disposition kinetics of difloxacin after intravenous, intramuscular and subcutaneous administration in calves, Vet. Res. Commun., 31, 467, 10.1007/s11259-006-3464-4 Kenny, 1989, Susceptibilities of genital mycoplasmas to the newer quinolones as determined by the agar dilution method, Antimicrob. Agents Chemother., 33, 103, 10.1128/AAC.33.1.103 Lacy, 1999, Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection, Antimicrob, Agents Chemother., 43, 672, 10.1128/AAC.43.3.672 Lees, 2002, Rational dosing of antimicrobial drugs: animals versus humans, Int. J. Antimicrob. Agents, 19, 269, 10.1016/S0924-8579(02)00025-0 Lister, 1999, Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae, J. Antimicrob. Chemother., 43, 79, 10.1093/jac/43.1.79 Lister, 1999, Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model, Antimicrob, Agents Chemother., 43, 1118, 10.1128/AAC.43.5.1118 Lode, 1998, Pharmacodynamics of fluoroquinolones, Clin. Infect. Dis., 27, 33, 10.1086/514623 Madaras-Kelly, 1996, Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model, Antimicrob. Agents Chemother., 40, 627, 10.1128/AAC.40.3.627 Marín, 2007, Pharmacokinetics and milk penetration of difloxacin after intravenous, subcutaneus and intramuscular administration to lactating goats, J. Vet. Pharmacol. Ther., 30, 74, 10.1111/j.1365-2885.2007.00818.x Marín, 2007, Pharmacokinetics after intravenous, intramuscular and subcutaneous administration of difloxacin in sheep, Res. Vet. Sci., 83, 234, 10.1016/j.rvsc.2007.01.005 Ramos, 2003, Simple and sensitive determination of five quinolones in food by liquid chromatography with fluorescence detection, J. Chromatogr. B, 789, 373, 10.1016/S1570-0232(03)00212-5 Smith, 1986, In vitro activity of A-56619 and A-56620, two new aryl-fluoroquinolone antimicrobial agents, Antimicrob. Agents Chemother., 29, 355, 10.1128/AAC.29.2.355 Stamm, 1986, In vitro evaluation of ABBOTT-56619 (difloxacin) and ABBOTT-56620: new aryl-fluoroquinolones, Antimicrob. Agents Chemother., 29, 193, 10.1128/AAC.29.2.193 Suárez, 2009, Disposition of difloxacin and its metabolite sarafloxacin in healthy chickens. 11th International EAVPT Congress. Leipzig (Germany), July 12–16, Abstract in J. Vet. Pharmacol. Ther., 32, 145 Sukul, 2009, Metabolism and excretion kinetics of 14C-labeled and non-labeled difloxacin in pigs after oral administration, and antimicrobial activity of manure containing difloxacin and its metabolites, Environ. Res., 109, 225, 10.1016/j.envres.2008.12.007 Toutain, 2002, The pharmacokinetic-pharmacodynamic approach to a rational dosage regimen for antibiotics, Res. Vet. Sci., 73, 105, 10.1016/S0034-5288(02)00039-5 Wagner, 1975 Wagner, 1976, Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data, J. Pharmacokinet. Biopharm., 4, 443, 10.1007/BF01062831 Walker, 2000, The use of fluoroquinolones for companion animal antimicrobial therapy, Aust. Vet. J., 78, 84, 10.1111/j.1751-0813.2000.tb10528.x Wolfson, 1985, The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro, Antimicrob. Agents Chemother., 28, 581, 10.1128/AAC.28.4.581 Wright, 2000, Application of fluoroquinolone pharmacodynamics, J. Antimicrob. Chemother., 46, 669, 10.1093/jac/46.5.669 Yamaoka, 1978, Application of akaike’s information criterion (AIC) in the evaluation of linear pharmacokinetic equations, J. Pharmacokinet. Biopharm., 6, 165, 10.1007/BF01117450